Boston Scientific Corporation
Boston Scientific Prices €2.0 Billion Senior Notes Offering
Summary
On February 22, 2024, Boston Scientific Corporation, through its wholly-owned subsidiary American Medical Systems Europe B.V., priced a €2.0 billion senior notes offering. The notes, due 2029 and 2032, were fully guaranteed by the Company. The proceeds, approximately €1.980 billion net, were intended to finance the acquisition of Axonics, Inc., repay existing debt, and cover related fees and expenses. The offering completed on February 27, 2024. Legal opinions regarding the validity of the notes were filed as exhibits.
Profitelligence Alerts
Get alerts for BSX
Be first to know when Boston Scientific Corporation files with the SEC.
Filing Categories
Exhibits (7)
Advertisement
About Boston Scientific Corporation
Boston Scientific Corporation, a leading global medical device company, is renowned for developing and supplying innovative health solutions. Its primary function is to design, manufacture, and market medical devices used in interventional medical specialties such as cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company's product offerings significantly impact sectors like health care, particularly those focusing on minimally invasive treatments. Boston Scientific's products help improve the quality of patient care and reduce the need for major surgery, thus playing a crucial role in modern healthcare systems. Their devices contribute to procedures that are less invasive, more effective, and often more economic, supporting better patient outcomes and quicker recovery times. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific provides its products to healthcare providers and institutions worldwide. In the financial markets, Boston Scientific Corporation holds significant influence as a major player in the healthcare industry, contributing to advancements in medical technology and shaping the future of patient care through research and development. Its presence underscores the importance of innovation in medical devices and its role in enhancing healthcare delivery.
Official SEC Documents
Advertisement